Floatz logo

jk-1201i

Triple Negative Breast Cancer (TNBC)

JenKem Technology Co., Ltd.Phase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

447 Active assets in the Triple Negative Breast Cancer (TNBC) cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

jk-1201i is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
56 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CCC
Indicative ·
53 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →